Prevalence of fatty liver disease in patients with inflammatory bowel disease: a transient elastography study on the basis of a controlled attenuation parameter
Objective: Inflammatory bowel disease (IBD) is a chronic
recurrent inflammatory disorder of the gastrointestinal tract
which has an unknown etiology. In this study, we aimed to
investigate the fatty liver disease frequency in IBD patients
using transient elastography (TE) which is a non-invasive and
accurate method for the diagnosis of liver fibrosis.
Material and Methods: The data were collected from
registered patients retrospectively. On the basis of previous
studies, a cut-off value of 238 dB/m for controlled attenuation
parameter (CAP) was used for the diagnosis of hepatic steatosis.
In this study we have also settled CAP value above 238 dB/m
as fatty liver.
Results: A total of 99 patients were enrolled in the study.
Mean age was 45.59 ± 11.72 years and 41 (41.4%) patients were
female. Fifty-eight patients (58.6%) had Crohn’s disease, 39
(39.4%) had ulcerative colitis and 2 (2.0%) had indeterminate
colitis. In 8 (8.1%) patients extra-large probe and in 91 (91.9%)
patients medium probe was used to detect liver steatosis. Fatty
liver disease was detected in 44 (44.4%) patients with IBD.
Conclusion: Despite the nutrition disorders in IBD,
fatty liver disease was seen in 44.4% of patients in our
cohort. However, fatty liver disease may be seen without any
aminotransferase elevation in IBD patients. Therefore, liver
steatosis should always be kept in mind and careful attention
should be paid during follow-up of patients with IBD in our
daily practice.
___
- 1. Rinella M E. Nonalcoholic fatty liver disease: a systematic
review. JAMA 2015;313:2263-73. doi:10.1001/
jama.2015.5370
- 2. EASL;EASD;EASO. Clinical Practice Guidelines for the
management of non-alcoholic fatty liver disease. J Hepatol
2015;64:1388-402. doi:10.1016/j.jhep.2015.11.004
- 3. Rockey D C, Caldwell S H, Goodman Z D, et al. Liver biopsy.
Hepatology 2009; 49: 1017-44. doi:10.1002/hep.22742
- 4. Schwenzer N F, Springer F, Schraml C, Stefan N, Machann J,
Schick F. Non-invasive assessment and quantification of liver
70 Kani et al.
Hepatic steatosis in inflammatory bowel disease Marmara Medical Journal 2019; 32: 68-70
steatosis by ultrasound, computed tomography and magnetic
resonance. J Hepatol 2009;51:433-45. doi:10.1016/j.
jhep.2009.05.023
- 5. Sasso M, Beaugrand M, de Ledinghen V, et al. Controlled
attenuation parameter (CAP): a novel VCTE guided
ultrasonic attenuation measurement for the evaluation of
hepatic steatosis: preliminary study and validation in a cohort
of patients with chronic liver disease from various causes.
Ultrasound Med Biol 2010; 36: 1825-35. doi:10.1016/j.
ultrasmedbio.2010.07.005
- 6. Sasso M, Miette V, Sandrin L, et al. The controlled attenuation
parameter (CAP): a novel tool for the non-invasive evaluation
of steatosis using Fibroscan. Clin Res Hepatol Gastroenterol
2012;36: 13-20. doi:10.1016/j.clinre.2011.08.001
- 7. Sasso M, Tengher-Barna I, Ziol M, et al. Novel controlled
attenuation parameter for noninvasive assessment of
steatosis using Fibroscan((R)): validation in chronic hepatitis
C. J Viral Hepat 2012;19:244-53. doi:10.1111/j.1365-
2893.2011.01534.x
- 8. de Ledinghen, V, Vergniol J, Foucher J, et al. Non-invasive
diagnosis of liver steatosis using controlled attenuation
parameter (CAP) and transient elastography. Liver Int 2012;
32:911-8. doi:10.1111/j.1478-3231.2012.02820.x
- 9. Boursier J, Cales P. Controlled attenuation parameter (CAP):
a new device for fast evaluation of liver fat? Liver Int
2012;32:875-7. doi:10.1111/j.1478-3231.2012.02824.x
- 10. Yılmaz Y, Ergelen R, Akin H, et al. Noninvasive detection
of hepatic steatosis in patients without ultrasonographic
evidence of fatty liver using the controlled attenuation
parameter evaluated with transient elastography. Eur J
Gastroenterol Hepatol 2013; 25:1330-34. doi:10.1097/
MEG.0b013e3283623a16
- 11. Yilmaz Y, Yesil A, Gerin F, et al. Detection of hepatic steatosis
using the controlled attenuation parameter: a comparative
study with liver biopsy. Scand J Gastroenterol 2014; 49: 611-
6. doi:10.3109/00365.521.2014.881548
- 12. Roman A L, Munoz F. Comorbidity in inflammatory
bowel disease. World J Gastroenterol 2011;17: 2723-33.
doi:10.3748/wjg.v17.i22.2723
13. Gisbert J P, Luna M, Gonzalez-Lama Y, et al. Liver injury
in inflammatory bowel disease: long-term follow-up study
of 786 patients. Inflamm Bowel Dis 2016;13:1106-14.
doi:10.1002/ibd.20160
- 14. Sourianarayanane A, Garg G, Smith T H, et al. Risk
factors of non-alcoholic fatty liver disease in patients with
inflammatory bowel disease. J Crohns Colitis 2013; 7: e279-
85. doi:10.1016/j.crohns.2012.10.015
- 15. Bargiggia S, Maconi G, Elli M, et al. Sonographic prevalence
of liver steatosis and biliary tract stones in patients with
inflammatory bowel disease: study of 511 subjects at a
single center. J Clin Gastroenterol 2003;36: 417-20. doi:
10.1097/00004.836.200305000-00012
- 16. Barbero-Villares A, Mendoza Jimenez-Ridruejo J, Taxonera
C, et al. Evaluation of liver fibrosis by transient elastography
(Fibroscan(R)) in patients with inflammatory bowel disease
treated with methotrexate: a multicentric trial. Scand J
Gastroenterol 2012;47:575-9. doi:10.3109/00365.521.2011.
647412
- 17. Thin L W, Lawrance I C, Spilsbury K, et al. Detection of liver
injury in IBD using transient elastography. J Crohns Colitis
2014; 8: 671-7. doi:10.1016/j.crohns.2013.12.006
- 18. Chao C Y, Battat R, Al Khoury A, et al. Co-existence of nonalcoholic fatty liver disease and inflammatory bowel disease:
A review article. World J Gastroenterol 2016;22:7727-34.
doi:10.3748/wjg.v22.i34.7727
- 19. Myers R P, Pollett A, Kirsch R, et al. Controlled Attenuation
Parameter (CAP): a noninvasive method for the detection of
hepatic steatosis based on transient elastography. Liver Int
2012;32:902-10. doi:10.1111/j.1478-3231.2012.02781.x
- 20. de Fazio C, Torgano G, de Franchis R, et al. Detection
of liver involvement in inflammatory bowel disease by
abdominal ultrasound scan. Int J Clin Lab Res 1992;21:314-
7. doi:10.1007/bf02591669
- 21. Riegler G, D’Inca R, Sturniolo G C, et al. Hepatobiliary
alterations in patients with inflammatory bowel disease:
a multicenter study. Caprilli & Gruppo Italiano Studio
Colon-Retto. Scand J Gastroenterol 198;33:93-8.
doi:10.1080/003.655.29850166275
- 22. Yamamoto-Furusho J K, Sanchez-Osorio M, Uribe M.
Prevalence and factors associated with the presence of
abnormal function liver tests in patients with ulcerative
colitis. Ann Hepatol 2010;9:397-401.
- 23. Bessissow T, Le N H, Rollet K, et al. Incidence and predictors
of nonalcoholic fatty liver disease by serum biomarkers in
patients with inflammatory bowel disease. Inflamm Bowel
Dis 2016;22:1937-44. doi:10.1097/mib.000.000.0000000832
- 24. Kaya E, Demir D, Alahdab Y O, et al. Prevalence of hepatic
steatosis in apparently healthy medical students: a transient
elastography study on the basis of a controlled attenuation
parameter. Eur J Gastroenterol Hepatol